P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma

We evaluated the safety and immunogenicity of the BNT162b2 vaccine in 52 patients with multiple myeloma (MM). Median age was 71.3 (range, 39.6-90.8) years. 26 (50%) patients had received active treatment including an immunomodulatory drug (IMiD) (n=21), an anti-CD38 monoclonal antibody (n=11) and/or...

Descripción completa

Detalles Bibliográficos
Autores principales: Malard, Florent, Gaugier, Béatrice, Gozlan, Joel, Bouquet, Lucie, Fofana, Djeneba, Van De Wyngaert, Zoe, Ikhlef, Souhila, Marjanovitch, Zora, Morand-Joubert, Laurence, Mohty, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Poster Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580180/
http://dx.doi.org/10.1016/S2152-2650(21)02276-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580180/
http://dx.doi.org/10.1016/S2152-2650(21)02276-X

Ejemplares similares